Stockscreener 앱 받기
12.10
4.39%
0.545
전일 마감가:
$11.55
열려 있는:
$11.7
하루 거래량:
428.68K
Relative Volume:
0.16
시가총액:
$1.38B
수익:
-
순이익/손실:
$-242.30M
주가수익비율:
-4.877
EPS:
-2.48
순현금흐름:
$-192.10M
1주 성능:
+9.90%
1개월 성능:
+9.80%
6개월 성능:
+47.39%
1년 성능:
+37.47%
1일 변동 폭
$11.58
$12.21
1주일 범위
$10.38
$12.21
52주 변동 폭
$3.72
$12.97
코젠트 바이오사이언시스 Stock (COGT) Company Profile
명칭
Cogent Biosciences Inc
전화
617-945-5576
주소
275 WYMAN STREET, WALTHAM
COGT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
12.09 | 1.53B | 0 | -242.30M | -192.10M | -2.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.27 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.35 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.46 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
644.33 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.25 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
코젠트 바이오사이언시스 Stock (COGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-11 | 다운그레이드 | Needham | Buy → Hold |
| 2024-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 개시 | Citigroup | Buy |
| 2023-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-12-08 | 개시 | JP Morgan | Overweight |
| 2023-04-28 | 개시 | Robert W. Baird | Outperform |
| 2023-03-27 | 재개 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-06-28 | 개시 | Guggenheim | Buy |
| 2021-10-11 | 개시 | H.C. Wainwright | Buy |
| 2021-06-09 | 재개 | Jefferies | Buy |
| 2020-12-23 | 개시 | Piper Sandler | Overweight |
| 2020-10-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
코젠트 바이오사이언시스 주식(COGT)의 최신 뉴스
Wedbush Lowers Earnings Estimates for Cogent Biosciences - MarketBeat
Leerink Partnrs Has Pessimistic Outlook of COGT Q3 Earnings - MarketBeat
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference - The Globe and Mail
Cogent Biosciences Reports First Quarter 2025 Financial Results - The Globe and Mail
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - The Globe and Mail
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing - The Globe and Mail
Cogent Biosciences to Participate in the Guggenheim Biotech Conference - The Globe and Mail
Q3 EPS Forecast for Cogent Biosciences Raised by Analyst - MarketBeat
Knott David M Jr Takes $1.28 Million Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Cogent Biosciences (NASDAQ:COGT) Stock - MarketBeat
Wedbush Reduces Earnings Estimates for Cogent Biosciences - MarketBeat
Cogent Biosciences price target lowered to $21 from $22 at H.C. Wainwright - MSN
HC Wainwright Issues Pessimistic Forecast for Cogent Biosciences (NASDAQ:COGT) Stock Price - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
How Investors Are Reacting To Cogent Biosciences (COGT) Widening Losses in Q2 and First Half 2025 - simplywall.st
Cogent Biosciences shares fall 1.64% intraday after Cogent Communications misses Q2 net loss per share estimates. - AInvest
Cogent Biosciences Reports Increased Losses Amidst Ongoing Development - The Globe and Mail
Cogent Biosciences Reports Positive Trial Results, Updates Financial Position - AInvest
Scotiabank Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17 - 富途牛牛
Needham Maintains Cogent Biosciences(COGT.US) With Hold Rating - 富途牛牛
COGT Stock Rating Maintained by HC Wainwright, Price Target Lowe - GuruFocus
Cogent Biosciences (COGT) Price Target Revised by Analyst - GuruFocus
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $18.70 Consensus Target Price from Brokerages - MarketBeat
Decoding Cogent Biosciences Inc (COGT): A Strategic SWOT Insight - GuruFocus
Promising Pipeline and Financial Stability Drive Buy Rating for Cogent Biosciences - TipRanks
Cogent Biosciences: KDJ Golden Cross and Bullish Marubozu Indicators Detected - AInvest
Cogent Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cogent Biosciences Reports Recent Business Highlights and Secon - GuruFocus
Cogent Biosciences' Q2 net loss widens as costs mount - TradingView
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results - GlobeNewswire
BRIEF-Cogent Biosciences Q2 Operating Expenses USD 75.581 Million - TradingView
Cogent's NonAdvSM Drug Trial Hits All Endpoints with 87% Response Rate, Two More Pivotal Results Coming - Stock Titan
Chart Analysts Warn of Resistance Near Cogent Biosciences Inc. PriceEntry Points For Growing Stocks Identified by Models - beatles.ru
What are analysts’ price targets for Cogent Biosciences Inc. in the next 12 monthsConsistently outstanding ROI - Jammu Links News
Should I hold or sell Cogent Biosciences Inc. stock in 2025Explosive returns - Jammu Links News
What drives Cogent Biosciences Inc. stock priceAchieve breakthrough gains with smart trades - Jammu Links News
Is it the right time to buy Cogent Biosciences Inc. stockTriple-digit returns - Jammu Links News
How strong is Cogent Biosciences Inc. company’s balance sheetGet daily updates on the hottest stocks - Jammu Links News
What is Cogent Biosciences Inc. company’s growth strategyGet real-time alerts on high-potential stocks - Jammu Links News
Y Intercept Hong Kong Ltd Sells 31,538 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
What makes Cogent Biosciences Inc. stock price move sharplyExplosive capital appreciation - Jammu Links News
What is the risk reward ratio of investing in Cogent Biosciences Inc. stockCapitalize on market trends with confidence - Jammu Links News
Cogent Biosciences (COGT) to Release Quarterly Earnings on Tuesday - MarketBeat
What institutional investors are buying Cogent Biosciences Inc. stockRetirement Planning Insights For 2025 - Jammu Links News
Published on: 2025-07-30 07:09:48 - metal.it
Key External Factors That Drive Cogent Biosciences Inc. Stock Price MovementsRisk Controlled Picks With Real Returns Outlined - metal.it
코젠트 바이오사이언시스 (COGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
0.06%
자본화:
|
볼륨(24시간):